For decades, researchers have debated how often overdiagnosis actually occurs. Estimates from randomized trials have differed sharply, with some studies suggesting that 30-50% of breast cancers detected through screening could fall into this category. Those figures have influenced international discussions about both the benefits and possible harms of population-based breast cancer screening.